Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques

Neurology

Volumn 75, Issue 13, 2010, Pages 1203-1210

  Sonnen, J A ^a   Larson, E B ^c   Walker, R L ^c   Haneuse, S ^c   Crane, P K ^a   Gray, S L ^a   Breitner, J C S ^b,d   Montine, T J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E;

ARTICLE; ATHEROSCLEROSIS; AUTOPSY; BRAIN DISEASE; BRAIN INFARCTION; CONTROLLED STUDY; DATA ANALYSIS; DEMENTIA; DISEASE SEVERITY; DRUG EXPOSURE; HUMAN; LEWY BODY; NEURITIC PLAQUE; NEUROFIBRILLARY TANGLE; NEUROIMAGING; POPULATION RESEARCH; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; AGED; ALZHEIMER DISEASE; BRAIN; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETICS; MALE; PATHOLOGY; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES;

EID: 77957952419     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f52db1     Document Type: Article

References (34)

1. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004;23: 159-169.
2. Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr 2005;5:2.
3. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008;70:17-24.
4. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-5714.
5. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001;22:983-991.
6. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008;1207:225-236.
7. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;72:1899-1905.
8. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008;70:2219-2225.
9. de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 2008;3:e1475.
10. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
11. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofe-coxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289: 2819-2826.
12. Thal LJ, Ferris SH, Kirby L, et al. A randomized, doubleblind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-1215.
13. Group AR, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68:1800-1808.
14. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007;62:406-413.
15. White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann NY Acad Sci 2002;977:9-23. (Pubitemid 35418132)
16. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropa-thology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66: 1837-1844.
17. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 2009;360:2302-2309.
18. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59:1737-1746.
19. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73-81.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
21. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
22. Drug Facts and Comparisons. St. Louis, MO: Facts & Comparisons; 2008.
23. Int'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
24. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
25. Zaccai J, Ince P, Brayne C. Population-based neuropatho-logical studies of dementia: design, methods and areas of investigation-a systematic review. BMC Neurol 2006;6:2.
26. Haneuse S, Schildcrout J, Crane P, Sonnen J, Breitner J, Larson E. Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology 2009;32:229-239.
27. Shie FS, Nivison M, Hsu PC, Montine TJ. Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator- activated receptor gamma. Curr Med Chem 2009;16:643-651.
28. Pratico D, Dogne JM. Vascular biology of eicosanoids and atherogenesis. Expert Rev Cardiovasc Ther 2009;7:1079-1089.
29. Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PLoS One;5:e9340.
30. Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007;25:913-924.
31. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007;99:91-98.
32. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006; 31:565-576.
33. Esposito E, Di Matteo V, Benigno A, Pierucci M, Cresci-manno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007;205:295-312.
34. Ton TG, Heckbert SR, Longstreth WT Jr, et al. Nonste-roidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006;21:964-969.